Table of Contents

• What is IZORLISIB MESILATE?
• Target Conditions
• How It Works
• Clinical Trial Details
• Eligibility Criteria
• Potential Benefits
• Safety Considerations

What is IZORLISIB MESILATE?

IZORLISIB MESILATE, also known as MEN1611, is a new drug being studied for the treatment of advanced breast cancer^[1]. It belongs to a class of medications called selective Class I PI3K inhibitors. This means it targets a specific protein in cancer cells that helps them grow and survive^[1].

Target Conditions

The drug is being investigated for two specific types of advanced breast cancer:

1. Locally advanced or unresectable PIK3CA and/or PTEN-altered metaplastic or non-metaplastic triple-negative breast cancer^[1].
2. Locally advanced or unresectable PIK3CA and/or PTEN-altered metaplastic HR-positive/HER2-negative breast cancer^[1].

Let’s break down these terms:

• Locally advanced or unresectable: This means the cancer has spread from where it started but is not yet widespread throughout the body. “Unresectable” means it cannot be completely removed by surgery.
• PIK3CA and PTEN: These are genes that, when altered, can contribute to cancer growth.
• Metaplastic: A rare and aggressive type of breast cancer.
• Triple-negative: A type of breast cancer that lacks three common receptors (estrogen, progesterone, and HER2).
• HR-positive/HER2-negative: Cancer cells that have hormone receptors but lack HER2 receptors.

How It Works

IZORLISIB MESILATE works by inhibiting a group of enzymes called PI3K (phosphatidylinositol-3-kinase). These enzymes are part of a signaling pathway that is often overactive in cancer cells, leading to uncontrolled cell growth and survival. By blocking this pathway, IZORLISIB MESILATE aims to slow down or stop cancer growth^[1].

Clinical Trial Details

The drug is currently being studied in a Phase II clinical trial called the SABINA study^[1]. This trial is:

• Multicenter: Conducted at multiple hospitals or research centers
• Two-cohort: Studying two groups of patients with different types of breast cancer
• Non-comparative: Not directly comparing the treatment to another therapy
• Open-label: Both patients and doctors know which treatment is being given

In this trial, IZORLISIB MESILATE is being combined with another drug called eribulin^[1].

Eligibility Criteria

To participate in the trial, patients must meet certain criteria, including:

• Be 18 years or older^[1]
• Have confirmed PIK3CA mutation or PTEN loss in their tumor^[1]
• Have received at least one, but no more than four, prior lines of systemic therapy for advanced disease^[1]
• Have adequate organ function and performance status^[1]

There are also several exclusion criteria, such as certain medical conditions or prior treatments, that would prevent participation^[1].

Potential Benefits

The main goals of the study are to assess:

• Clinical Benefit Rate (CBR): The percentage of patients whose cancer shrinks or remains stable for at least 12 weeks^[1]
• Objective Response Rate (ORR): The proportion of patients whose tumors shrink significantly^[1]
• Duration of Response (DoR): How long the tumor response lasts^[1]
• Progression-Free Survival (PFS): How long patients live without their cancer getting worse^[1]
• Overall Survival (OS): How long patients live overall^[1]

Safety Considerations

As with any new treatment, there may be side effects or risks. The study will closely monitor patients for any adverse events^[1]. Some potential areas of concern include:

• Effects on blood cell counts
• Liver and kidney function
• Heart rhythm changes
• Gastrointestinal issues

It’s important to note that IZORLISIB MESILATE is still in the research phase. While it shows promise, more studies are needed to fully understand its effectiveness and safety profile for treating advanced breast cancer.